Long-term improvement during tadalafil therapy in a patient with pulmonary hypertension secondary to pulmonary Langerhans cell histiocytosis  by Nemoto, Kenji et al.
lable at ScienceDirect
Respiratory Medicine Case Reports 18 (2016) 54e57Contents lists avaiRespiratory Medicine Case Reports
journal homepage: www.elsevier .com/locate /rmcrCase reportLong-term improvement during tadalaﬁl therapy in a patient with
pulmonary hypertension secondary to pulmonary Langerhans cell
histiocytosis
Kenji Nemoto a, *, Shuji Oh-ishi a, Toshihide Inui a, Mariko Nakazawa a, Kentaro Hyodo a,
Masayuki Nakajima a, Jun Kanazawa a, Yukiko Miura a, Takio Takaku a, Yuko Minami b,
Kenji Hayashihara a, Takefumi Saito a, Yoshinori Kawabata c
a Department of Respiratory Medicine, National Hospital Organization, Ibarakihigashi National Hospital, Ibaraki, Japan
b Department of Pathology, National Hospital Organization, Ibarakihigashi National Hospital, Ibaraki, Japan
c Division of Diagnostic Pathology, Saitama Prefectural Cardiovascular and Respiratory Centre, Saitama, Japana r t i c l e i n f o
Article history:
Received 30 March 2016
Received in revised form
20 April 2016
Accepted 23 April 2016
Keywords:
Pulmonary arterial hypertension
Pulmonary langerhans cell histiocytosis
Phosphodiesterase-5 inhibitor
Tadalaﬁl* Corresponding author. National Hospital Organiz
Hospital, 825, Terunuma, Tokai-mura, Naka-gun, Ibar
E-mail address: nemoken1124@yahoo.co.jp (K. Ne
http://dx.doi.org/10.1016/j.rmcr.2016.04.008
2213-0071/© 2016 The Author(s). Published by Elsevie
).a b s t r a c t
Pulmonary arterial hypertension (PAH) secondary to pulmonary Langerhans cell histiocytosis (PLCH) is
known to be a relatively common complication and is associated with a poor prognosis. However, the
optimal therapeutic approach for these cases remains to be established. A 57-year-old man visited our
hospital because of a progressive dry cough. A thoracic computed tomography examination showed a
combination of diffuse thick-walled cysts and reticulonodular shadows that were predominant in
bilateral upper lobes of the lungs. He was diagnosed as having PLCH based on the results of video-
assisted thoracoscopic lung biopsies. During a 3-year clinical course, his condition deteriorated despite
smoking cessation. A systemic evaluation demonstrated precapillary PAH caused by PLCH (PAH-PLCH),
and treatment with tadalaﬁl, a phosphodiesterase-5 inhibitor, was started. During a 50-month period of
treatment with tadalaﬁl, improvements in his dyspnea, 6-min walking distance, and hemodynamics
were maintained without either overt hypoxemia or pulmonary edema. We considered that tadalaﬁl
therapy may be a useful option in the treatment of patients with PAH-PLCH.
© 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pulmonary Langerhans cell histiocytosis (PLCH) is characterized
by the inﬁltration of large numbers of Langerhans cells to the
involved tissues and is a rare lung disease that occurs predomi-
nantly in young smokers [1]. The clinical course and prognosis of
PLCH are unpredictable. Although most patients with PLCH recover
spontaneously or remain in a stable condition without treatment
after smoking cessation, some patients experience progressive
respiratory impairment related to a deleterious change in lung
function or to the development of pulmonary arterial hypertension
(PAH) [1]. Precapillary PAH is an important complication in patients
with PLCH, since PAH is associated with a poor prognosis [2].
However, little information on the optimal treatment of PAH causedation, Ibarakihigashi National
aki 319-1113, Japan.
moto).
r Ltd. This is an open access articleby PLCH (PAH-PLCH) is available [3e6]. Indeed, the limited data
available for PAH-PLCH suggests that PAH-speciﬁc therapies are
associated with a long term improvement in hemodynamics [4e6].
Here, we present a patient with PAH-PLCH who has maintained
a long-term improvement by undergoing treatment with tadalaﬁl,
a phosphodiesterase-5 inhibitor.2. Case report
A 57-year-old man who had no signiﬁcant past medical history
visited our hospital in 2007 because of a progressive dry cough. He
was a current smoker (60 pack-years) and had worked as a foundry
worker with respiratory protection until hospital admission. A
chest radiography (Fig. 1A) and computed tomography (Fig. 1B and
C) showed a combination of diffuse thick-walled cysts and retic-
ulonodular shadows that were predominant in the upper lobes of
the lungs. Pulmonary function tests demonstrated an almost
normal pattern, except for a decrease in the carbon monoxideunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/
Fig. 1. (A) Chest X-ray showing diffuse cysts with reticular shadows in bilateral lung ﬁelds. (B, C) Chest CT showing diffuse irregular- and thick-walled cysts with reticulonodular
shadows that were predominant in the upper lobes of the lungs.
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biochemical, and serologic tests were within the normal ranges.
Transthoracic echocardiography showed a normal cardiac image. A
bronchoalveolar lavage analysis and transbronchial lung biopsy did
not reveal a deﬁnitive diagnosis. Therefore, video-assisted thor-
acoscopic lung biopsies of the right upper and lower lobes were
performed, and multiple cystic lesions and nodular inﬁltrates with
ﬁbrosis formed from various types of cells, but mostly histiocytes
and eosinophils, were observed (Fig. 2A and B). These histiocytes
had a convoluted irregular nucleus and a pale eosinophilic cyto-
plasm that stained strongly for anti-CD1a and were identiﬁed as
Langerhans cells (Fig. 2C). Based on these histological characteris-
tics, a diagnosis of PLCH was established. The patient stopped
smoking and changed his occupational environment after theTable 1
Overview of clinical, function and haemodynamic features before and after tadalaﬁl ther
Variables 2007 2009 2010 (Baseline) 1 month
NYHA class I II IV III
NT pro BNP (pg/ml) ND 61.6 63.3 43.3
6MWT distance (m) ND 265a 255a 200a
6MWT SpO2, percentage
of decrease (%)
ND 2a 5a 9a
PaO2 at rest (mmHg) 83.1 74.2b 56.6b 52.9b
PaCO2 at rest (mmHg) 41.8 44.7b 42.8b 46.5b
VC, % pred (%) 106.9 97.4 64.5 61.9
FEV1, % pred (%) 103.3 72.9 49.8 49.8
DLco, % pred (%) 70.2 49.1 34.6 37.3
PAP systolic/diastolic
(mmHg)
ND ND 51/24 51/27
Mean PAP (mmHg) ND ND 34 34
Mean PCW (mmHg) ND ND 6 13
PVR (dynes/s/cm5) ND ND 638.3 342.5









NYHA: New York Heart Association; NT pro BNP: N-terminal pro-brain naturiuretic pept
dioxide tension; FVC: forced vital capacity; FEV1: forced expiratory volume in1 second;
pulmonary capillary wedge pressure; PVR: pulmonary vascular resistance; CI: cardiac in
a Nasaloxygen, 5 L/min.
b Nasaloxygen, 2 L/min.surgical biopsy.
In 2009, despite the complete cessation of smoking, he began to
experience exertional dyspnea (New York Heart Association
[NYHA] functional class II) with hypoxemia. A transthoracic echo-
cardiography showed no evidence of right arterial overloading, but
pulmonary function testing showed an obstructive impairment and
a decline in DLco (Table 1). Therefore, long-term nasal oxygen
therapy was started.
In 2010, he presented with increased dyspnea (NYHA func-
tional class IV) and marked hypoxemia. Pulmonary function tests
demonstrated the progression of obstructive impairment and a
reduction in vital capacity (VC) and Dlco (Table 1). The radio-
graphic ﬁndings also showed the progression of emphysematous
change. Right heart catheterization (RHC) was performed for theapy.
15 months 30 months 40 months 50 months
II II II II
25.7 21.5 39.1 26.3
ND 230a 305a 310a
ND 2a 5a 7a
ND 70.3b 74.2b 83.8b
ND 39.7b 41.5b 46.9b
75.1 72.8 66.2 73.5
50.4 52.6 48.4 52.4
44.2 38.4 34.9 50.0
ND 34/18 34/16 32/13
ND 25 24 21
ND 8 9 5
ND 376.1 321.1 387.7
ND 2.23 2.33 2.00








ide; 6MWT: 6-min walk test; PaO2: arterial oxygen tension; PaCO2: arterial carbon
DLco: transfer factor for carbon monoxide; PAP: pulmonary artery pressure; PCW:
dex; ND: not determined.
Fig. 2. (A, B) Histological ﬁndings show multiple cystic lesions and nodular inﬁltrates with ﬁbrosis formed from various types of cells, but mostly histiocytes and eosinophils
(hematoxylin and eosin, A; panoramic view, B; in box, 400). (C) An immunostaining study revealed the histiocytes to be Langerhans cells (anti-CD1a antibody, 400). (D)
Histological ﬁndings of the pulmonary arteries away from the LCH lesions show mild medial thickening and intimal ﬁbrosis.
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precapillary PAH with a mean pulmonary arterial pressure
(mPAP) of 34 mmHg, a cardiac index of 2.02 L/min/m2, and a
pulmonary vascular resistance (PVR) of 638.3 dyne/s/cm5. Since
other causes of PAH, such as pulmonary embolism, systemic
disease, HIV infection, and portal hypertension, seemed to be
negative, the patient was diagnosed as having PAH-PLCH. A
retrospective analysis of the previous specimens of lung biopsies
revealed mild medial thickening and intimal ﬁbrosis in the pul-
monary arteries away from the LCH lesions; however, it was not
related to histological features of advanced PAH (Fig. 2D). He was
treated with corticosteroid therapy (prednisolone, 0.5 mg/kg/
day) for 1 month, but his symptoms did not improve. Therefore,
tadalaﬁl therapy was started.
After one month of tadalaﬁl therapy, his dyspnea decreased
(NYHA functional class III) and his hemodynamics improved (car-
diac index, 2.97 L/min/m2; PVR, 342.5 dyne/s/cm5), although a
temporal worsening of hypoxemia and the 6-min walking distance
(6MWD) were conﬁrmed (Table 1). During a 50-month period of
treatment with tadalaﬁl, the improvements in his dyspnea (NYHA
functional class II), hypoxemia, and 6MWD were maintained. In
addition, RHC ﬁndings showed sustained improvements in pul-
monary arterial pressure and pulmonary vascular resistance
(Table 1).3. Discussion
This case was diagnosed as PLCH based on a lung biopsy, and the
patient developed precapillary PAH three years after the initial
diagnosis. The long-term use of tadalaﬁl in this case was well
tolerated and safe, leading to sustained improvements in dyspnea,
exercise capacity and hemodynamics.
Chronic lung diseases such as COPD and chronic interstitial lung
disease, particularly those combined with pulmonary ﬁbrosis and
emphysema, are known to be associated with a high incidence of
PAH [7]. Although PLCH is an uncommon lung disease in compar-
ison with the above-mentioned diseases, there have been some
reports of PAH during the course of PLCH. In a retrospective study of
39 patients with PLCH who underwent lung transplantation, PAH
was detected in 92% of the cases and was moderate-to-severe
(mPAP >35 mmHg) in 72.5% [8]. Therefore, this study suggested
that PAH is a common feature among patients with end-stage PLCH
[8]. On the other hand, Chaowalit et al. reported that PAH is not
limited to patients with end-stage PLCH [9]. This study also sug-
gested that the development of PAH in patients with PLCH may be
associated with an increased mortality (hazard ratio, 22.8; 95%
conﬁdence interval, 7.6 to >68.9; P < 0.001) [9]. These ﬁndings
indicate that PAH is a relatively common and important compli-
cation of PLCH.
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patients with chronic lung disease because of an increased imbal-
ance in ventilation/perfusion caused by the inhibition of hypoxic
pulmonary vasoconstriction [10]. Indeed, the present case revealed
the progression of hypoxemia after a month of tadalaﬁl therapy,
despite the improvement in his pulmonary hemodynamics.
Although the pathophysiology of PAH associated with PLCH is not
well understood, this clinical course seems to indicate that pul-
monary vasoconstriction caused by chronic hypoxemia is an
important mechanism in the pathogenesis of PAH-PLCH. On the
other hand, our case exhibited sustained improvements in dyspnea,
exercise capacity, hemodynamics, and hypoxemia during long term
treatment with tadalaﬁl. These results indicate that mechanisms
other than hypoxic vasoconstriction may be responsible for PAH-
PLCH. In the present case, the lung tissues specimen revealed
mild medial thickening and intimal ﬁbrosis in pulmonary vessels
unrelated to the LCH lesions, though it was not a direct evidence of
PAH. Since the blood ﬂow at the lesions have been predicted to
decrease as a result of disease progression of the LCH, the excessive
blood ﬂow in the remaining vessels away from the LCH lesions may
have induced the PAH. Therefore, the effects of tadalaﬁl therapy on
PAH-PLCH in our case may have been induced by the dilation of
vessels unrelated to the LCH lesions. In addition to these mecha-
nisms, Fortoukh et al. [2] reported that the cause of PAH-PLCH may
be related to an intrinsic pulmonary vascular disease independent
of the involvement of small airways and lung parenchyma injury. In
this report, these vascular abnormalities were observed in areas
away from PLCH lesions in half of the patients, therefore, Fortoukh
et al. speculated that the PLCHmay play a certain role in the genesis
of vascular abnormalities through the production of cytokines and
growth factors [2]. However, we cannot address whether good
responsiveness to treatment with tadalaﬁl in our case support
Fortoukh's hypothesis. Therefore, further clinical studies are
needed to clarify the mechanisms of PAH-PLCH.
The efﬁcacy of PAH-speciﬁc therapies for PAH-PLCH has not
been well discussed in medical literature. Some previous reports
have indicated that the pulmonary venules are involved in the
disease process that is responsible for PAH-PLCH [2,11]. Therefore,
the use of PAH-speciﬁc therapies has long been considered haz-
ardous in PAH-PLCH patients because of the risk of pulmonary
edema. However, Kiakouma et al. reported a patient with PAH-
PLCH who was treated using the dual endothelin receptor antago-
nist bosentan and exhibited clinical, functional, and hemodynamic
improvements, and these beneﬁts were maintained for a total of 7
years [5]. In addition, Pavec et al.'s study evaluated patients with
PAH-PLCH who underwent short-term and long-term treatment
(5.5 ± 2.5 months and 16 ± 4 months after baseline in 12 and 10
patients, respectively) and, suggested that PAH-speciﬁc therapy
may improve the WHO function class and hemodynamics without
oxygen worsening or pulmonary edema [4]. Recently, May et al.reported that a patient with PAH-PLCH responded well to PAH-
speciﬁc therapies included a tadalaﬁl, and echocardiography and
WHO function class improvement were sustained over a 10 year
follow-up period [6]. In our case, tadalaﬁl therapy was associated
with an improvement in the WHO function class, 6MWD, and he-
modynamics without oxygen worsening. Furthermore, these im-
provements were sustained over a 50-month follow-up period.4. Conclusion
In the present case, although a temporal worsening of hypox-
emia occurred during the initial phase of treatment, we conﬁrmed
that a long-term improvement was obtained in a patient with PAH-
PLCH who was treated with tadalaﬁl, without any apparent com-
plications. Therefore, tadalaﬁl therapy may be a useful option for
the treatment of patients with PAH-PLCH.Conﬂict of interest
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